Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451

GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1 (GT1) HCV infection. Key preclinical properties of GS-9451, including in vitro antiviral activity, selectivity, cross-resistance, and combination activity, as well as pharmacokinetic...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Yang, Huiling, Robinson, Margaret, Corsa, Amoreena C., Peng, Betty, Cheng, Guofeng, Tian, Yang, Wang, Yujin, Pakdaman, Rowchanak, Shen, Marian, Qi, Xiaoping, Mo, Hongmei, Tay, Chin, Krawczyk, Steve, Sheng, X. Christopher, Kim, Choung U., Yang, Chris, Delaney, William E.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society for Microbiology 2014
נושאים:
Antiviral Agents
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3910871/
https://ncbi.nlm.nih.gov/pubmed/23939899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00487-13
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים